Figure 1 | Scientific Reports

Figure 1

From: Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis

Figure 1

Unadjusted results from CT-based body composition analysis before (T0) and after (T1) elexacaftor/tezacaftor/ivacaftor therapy. Significant increases of muscle, IMAT, EAT, PAT, SAT and TAT ratios were observed between baseline (T0) and follow-up (T1) analysis of body composition. Bone volume was stable and utilized as the denominator for calculating body size-adjusted ratios. Statistics: Line at median. P-value was determined using Wilcoxon signed rank test. * p < 0.05; ** p < 0.01; *** p < 0.001. TAT, total adipose tissue; IMAT, intra- and intermuscular adipose tissue; EAT, epicardial adipose tissue; PAT, paracardial adipose tissue; SAT, subcutaneous adipose tissue.

Back to article page